Spruce Biosciences (@Spruce_Bio) header
Spruce Biosciences (@Spruce_Bio) profile picture

Where science meets compassion to deliver targeted therapies for serious neurological disorders.

San Francisco Bay Area
Joined February 2018
Photo by Spruce Biosciences (@Spruce_Bio)Photo by Spruce Biosciences (@Spruce_Bio)Photo by Spruce Biosciences (@Spruce_Bio)Photo by Spruce Biosciences (@Spruce_Bio)Photo by Spruce Biosciences (@Spruce_Bio)Photo by Spruce Biosciences (@Spruce_Bio)Photo by Spruce Biosciences (@Spruce_Bio)Photo by Spruce Biosciences (@Spruce_Bio)Photo by Spruce Biosciences (@Spruce_Bio)Photo by Spruce Biosciences (@Spruce_Bio)
Tomorrow at 1:30 p.m. ET, Jonathan Wolleben of @CitizensBank, will host a virtual KOL call titled “Understanding the Unmet Need in MPS IIIB,” featuring Dr. Cara O’Neill, Chief Science Officer of the @CureSanfilippoF. Register: netroadshow.com/events/login… #MPSIIIB
2
128
On World Sanfilippo Awareness Day, we honor children and families living with Sanfilippo Syndrome. Their strength and hope inspire us to advance TA-ERT, an investigational therapy designed to address the underlying enzyme deficiency in MPS IIIB. #WorldSanfilippoDay
10
202
Today we reported our Q3 2026 financial results and provided a corporate update, including that our planned BLA submission for investigational TA-ERT is on track for December. Read the full press release: investors.sprucebio.com/news… $SPRB
1
7
1,018
We announced the separation of our CRHX-101 (formerly SPR-202) program into Adrenyx Biosciences, intended to become an independent public company. CRHX-101 is a preclinical-stage antibody targeting an upstream driver of classic CAH. investors.sprucebio.com/news… $SPRB #Adrenyx #CAH
10
937
Our CEO, Javier Szwarcberg, will participate in a fireside chat at the Guggenheim 3rd Annual Healthcare Innovation Conference on Nov. 10 at 11:30 a.m. ET. Access the live webcast here: event.summitcast.com/view/oV… $SPRB
3
5
787
In MPS IIIB, deficient NAGLU enzyme activity allows heparan sulfate to build up in cells throughout the body, including the brain. Investigational TA-ERT is designed to deliver the missing enzyme directly to the CNS; it is not approved by FDA. MPS3BStudy.com
1
2
234
We're looking forward to participating in a fireside chat next week at the Craig-Hallum Virtual Biotech Catalyst Conference. Access the webcast here: investors.sprucebio.com/news… $SPRB
6
716
Today’s #SpruceRoots spotlight is Meghan Bowler, PhD. Meghan helps turn complex clinical trial data into insights that support our planned BLA submission for TA-ERT in MPS IIIB and help bring us closer to making a meaningful difference for patients & families affected by MPS IIIB
1
1
4
268
#MPSIIIB natural history data will be presented at the 55th Child Neurology Society Annual Meeting in Montréal. Poster #235 | Oct 15 | 12:30–1:45 & 5:30–7:30 p.m. EDT Details: investors.sprucebio.com/news… #Sanfilippo #RareDisease #CNS2026
1
6
235
We were honored to welcome Dr. Paul Harmatz and an MPS IIIB caregiver to our recent All Hands. Hearing directly from the community keeps patients and families at the heart of our work. #RareDisease #MPSIIIB
143
Our intern program this year welcomed Amelia Graves, Anisa Mody and Trenton Chan to the Spruce team for the summer. We’re proud to celebrate their time at Spruce and help foster the next generation of biotech leaders.
1
160
We were proud to sponsor #ADVANCE2026. VP, Clinical Development Jessica Cohen Pfeffer, MD, shared updates on our Phase 3 TrAnsform Study of investigational TA-ERT. We were honored to connect with the Sanfilippo community.
175
Next week, our CEO Javier Szwarcberg will present at the H.C. Wainwright 28th Annual Global Investment Conference in New York. Access the live webcast here: journey.ct.events/view/e8359… $SPRB investors.sprucebio.com/news…
1
4
658
Earlier this month, the Spruce team attended the @MPSSociety Family Conference to listen, learn, and connect with members of the MPS IIIB community. Thank you to the families,caregivers, and advocates who shared their experiences. #RareDisease #MPSIIIB $SPRB
9
665
We’re proud to launch MPS3BStudy.com, a resource for families and caregivers of children with MPS IIIB, with information about the planned expanded access program and TrAnsform confirmatory study of investigational TA-ERT. $SPRB investors.sprucebio.com/news…
1
12
1,063
We announced today positive pre-BLA meetings with the FDA and confirmed its TA-ERT BLA submission remains on track for Q4 2026. Another important step forward in addressing the unmet needs of the MPS IIIB community. $SPRB investors.sprucebio.com/news…
1
2
2
31
2,862
Our CMO Adrian Quartel, M.D., FFPM is featured in @statnews’ “Up and Down the Ladder”: statnews.com/pharmalot/2026/… Adrian gave a glimpse into his science-driven leadership and thoughtful approach to drug development, as well as what keeps him grounded outside of work.
1
185
We announced our Q2 2026 results today. Visit our News & Events page for updates on the TA-ERT program, including our progress towards our planned BLA submission and confirmatory study of TA-ERT for the treatment of MPS IIIB. Full release: investors.sprucebio.com/news… $SPRB
1
4
1,442
Partnership with the patient community is critical to advancing progress in rare disease. We are proud to work alongside @CureSanfilippo and @MPSSociety to help expand access to TA-ERT for children and families affected by MPS IIIB. $SPRB investors.sprucebio.com/news…
1
7
965
Welcome Jessica Cohen Pfeffer, M.D., to Spruce as Vice President, Clinical Development. Her expertise in rare disease drug development and enzyme replacement therapies will be invaluable as we advance TA-ERT for Sanfilippo Syndrome Type B (MPS IIIB). $SPRB investors.sprucebio.com/news…
3
1,169